Bridging Gaps in Global Health
Galenica has forged partnerships with leading manufacturers and CROs worldwide, securing numerous marketing authorizations across our regions. Our unwavering commitment is to expand access to innovative and cost-sensitive alternatives, improving healthcare options for a broader patient base.
Supported by a robust infrastructure, we facilitate developing and commercializing specialty pharmaceuticals across a diverse therapeutic range. Our involvement spans from spearheading innovative therapies to championing orphan drugs for rare diseases, ensuring accessibility in geographies with limited healthcare resources. Galenica Health is proud to collaborate with global NGOs and government entities to provide access to specialty pharmaceuticals to the less privileged aimed at advancing human welfare.
Hemato-Oncology
• Monoclonal antibodies.
• Recombinant drugs.
• Colony-stimulating factors.
• Pegylated proteins.
• Liposomal therapies.
• Albumin-bound nanoparticles.
• Anti-emetics.
• Tyrosine kinase inhibitors.
Nephrology
• Vitamin D analogs.
• Iron Supplements.
• Erythropoiesis-stimulating agents.
• BFGF (fibroblast growth factor)
• Phosphate Binders.
• Calcimimetics.
Infectious Diseases
• Liposomal Amphotericin B.
• HIV fusion inhibitors.
• Protein-synthesis inhibitors.
• NRTI / NtRTI.
Immunology
• TNF inhibitors.
• Immunomodulators.
• Human immunoglobulin.
• Tetanus immunoglobulin.
• Immunosuppressors.
Rare Diseases
• Glucocerebrosidase enzyme replacement.
• Iduronate-2-sulfatase enzyme replacement.
• PEG L-Asparaginase.
• Erwinia L-Asparaginase.
• Recombinant Factor VIII.
• Antifibrotics.
Abcertin
Composition:
Imiglucerase 200 I.U./ vial.
Imiglucerase 400 I.U./ vial.
Indication: For use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of type 1 Gaucher disease.
Pack size: Box containing one vial.
Alfusid
Composition: Albuvirtide 160 mg/vial.
Indication: Treatment for patients with HIV who maintain replication of the virus despite being in antiretroviral therapy in combination with other antiretroviral agents.
Pack size: Box containing one vial.
Aveskad
Composition: Bevacizumab 25 mg/mL.
Indication: Adult patients with advanced non-small-cell lung cancer.
Pack size: Box containing one vial.
Bonipar
Composition: Teriparatide 250 mcg/mL.
Indication: Severe osteoporosis.
Pack size: Box containing one pre-filled pencil of 3 mL + 30 needles.
Curesil
Composition: Recombinant human fibroblast growth factor 70,000 I.U.
Indication: Promotes wound healing.
Pack size: Box containing one vial, a sterile water for injection ampoule and a spray pump.
Dasmiba
Composition: Dasatinib 50 mg/tablet.
Indication:
• Treatment of chronic myeloid leukemia in chronic, accelerated or blast phase, with resistance or intolerance to treatment with Imatinib.
• Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or lack of tolerance to previous treatment with Imatinib.
• Treatment of newly diagnosed chronic-phase chronic myeloid leukemia (first-line treatment).
Pack size: Available in 7 x 50mg Tabs. Per box.
Epronex
Composition: Erythropoietin 10,000 I.U. and 4,000 I.U.
Indication: Anemia resulting from renal failure and mobilization of red blood cells during the perioperative period.
Pack size: Box containing one prefilled syringe of 1 mL.
Filgrastim
Concentration:
Filgrastim 300 mcg/mL.
Filgrastim 480 mcg/1.6 mL.
Indication: Neutropenia and promote increased neutrophils after bone marrow transplantation.
Pack size: Box containing 1 vial.
Humanta
Concentration: Adalimumab 40 mg/0.8 mL.
Indication: Ankylosing spondylitis.
Pack size: Box containing one pre-filled syringe.
Hunterasa
Concentration: Idursulfatase-B 2 mg/mL.
Indication: Patients with Hunter syndrome.
Pack size: Box containing one vial.
Human Immunoglobulin
Concentration: Human immunoglobulin 5 g/100 mL.
Indication: Primary immunodeficiencies, secondary immunodeficiencies and autoimmune diseases.
Pack size: Box containing one bottle.
Tetanus Immunoglobulin
Concentration: Tetanus immunoglobulin 250 I.U./2.5 mL.
Indication: Passive protection of individuals who have suffered from a tetanus-prone wound.
Pack size: Box containing one vial.
LeucoSpar
Concentration: L-Asparaginase 10,000 I.U.
Indication: Acute lymphoblastic leukemia.
Pack size: Box containing one vial.
Leukat
Concentration: Azacitidine 100 mg.
Indication: Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML).
Pack size: Box containing one vial.
Miricet
Composition:
Cinacalcet hydrochloride 30 mg/tablet.
Cinacalcet hydrochloride 60 mg/tablet.
Indication:
• Treatment of secondary hyperparathyroidism in patients with chronic end-stage renal disease on dialysis.
• Treatment of hypercalcemia in patients with parathyroid carcinoma.
• Treatment of hypercalcemia in patients with primary hyperparathyroidism who cannot be treated.
Pack size:
Available in 30 x 30 coated tablets per bottle / 30 x 60 coated tablets per bottle.
Narcepta
Composition: Etanercept 25 mg/vial lyophilized powder for injection.
Indication:
• Treatment of active rheumatoid arthritis moderate to severe in adults when the response to disease-modifying antirheumatic drugs, including methotrexate, has been insufficient.
• Treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from 4 to 17 years, who have had an insufficient response, or who have a proven intolerance to methotrexate.
• Treatment of active and progressive psoriatic arthritis in adults when the response to a previous therapy with disease-modifying antirheumatic drugs has been insufficient.
• Treatment of severe ankylosing spondylitis in adults, who have not had an adequate response to conventional therapy.
• Treatment of adults with moderate to severe plaque psoriasis who have not responded, or who have contraindicated, or who do not tolerate other systemic therapy including Ciclosporin, Methotrexate, or PUVA.
Pack size: Box containing one vial.
Paltro
Concentration:
Palonosetron 0.25 mg/5 mL.
Palonosetron 0.075 mg/1.5 mL.
Indication:
• Prevention of acute nausea and vomiting associated with initial and repeated courses of cancer chemotherapy doses.
• Prevention and treatment of nausea and vomiting in the post-operative period.
Pack size:
Box containing one ampoule.
Box containing 10 ampoules.
Parvidex
Composition: Paricalcitol 5 mcg/ ampoules.
Indication:
• Treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) stages 3 to 5.
• Prevention and treatment of secondary hyperparathyroidism, associated with stage 5D Chronic Kidney Disease on hemodialysis or peritoneal dialysis.
Pack size: Available in 5 x 1mL ampoule per box.
Peginasa
Composition: Pegaspargasa 3750 U.I. /vial.
Indication: First line of acute lymphoblastic leukemia (ALL) and hypersensitivity to Asparginase.
Pack size: Available in 5 mL per bottle.
Rexalta
Composition: Glatiramer acetate 20 mg/mL.
Indication: Multiple sclerosis.
Pack size: Box containing 28 prefilled syringes and 28 alcohol wipes.
Sevagel
Composition: Each coated tablet contains Sevelamer carbonate 800 mg, excipients q.s.
Indication: Control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis.
Pack size: Available in 30 x 800mg Tabs. Per bottle.
